Drug Trial Radar · NCT02767947
Safety and Efficacy of Product 33525 (Luliconazole Cream 1%) in Pediatric Participants With Tinea Corporis
Last checked: Nov 20, 2026Latest source record: Nov 27, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
75
Actual
Start
Feb 8, 2016
Primary completion
Jun 29, 2016
Study completion Sep 22, 2016
Sponsor
- Lead sponsor
- Bausch Health Americas, Inc.Industry
- Sponsor type
- Industry
- First posted
- May 11, 2016
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 2 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this study was to evaluate the safety, efficacy, and pharmacokinetics of luliconazole cream 1% when applied topically for 7 days in pediatric participants 2 years to 17 years of age (inclusive) with tinea corporis.
Conditions
- Tinea Corporis
Interventions
Luliconazole Cream 1%Drug
Luliconazole cream will be applied per schedule specified in the arm.
Vehicle CreamDrug
Vehicle cream will be applied per schedule specified in the arm.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Circulating Plasma Concentration of Luliconazole at Day 7 (Pre-Dose)Time frame: Pre-dose (within 15 minutes prior to the final dose of the drug) on Day 7
- Circulating Plasma Concentration of Luliconazole at Day 7 (6 Hours Post-Dose)Time frame: 6 hours after the final dose of the drug on Day 7
Locations
3 sites in 2 countries. Site status is shown where the registry gives one.
Valeant Site 03
San Cristobal, Dominican Republic
Valeant Site 01
Santo Domingo, Dominican Republic
Valeant Site 02
San Pedro Sula, Honduras
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.